

TABLE OF CONTENTS

12. Ethics, Patents and Regulatory issues	6
Introduction	6
Ethical concerns about genetic diagnosis	6
Ethical guidelines for molecular diagnostics	7
Ethical aspects of direct-to-consumer genetic services	8
US public attitudes about genetic testing	9
Opinion of European geneticists about DTC genetic testing	9
Genetic testing for susceptibility to adult-onset cancer	9
Ethics of preimplantation genetic diagnosis	10
<i>Preimplantation genetic diagnosis to screen for hereditary diseases</i>	10
<i>PGD to test for susceptibility to cancer</i>	10
<i>PGD and stem cells</i>	11
Genetic research on stored tissues	11
Informed consent in clinical trials of in vitro devices	12
Concluding remarks about ethical issues	12
Insurance underwriting and gene tests	12
<i>Should genetic information be available to health insurers?</i>	13
<i>A need for the re-examination of current views</i>	13
<i>Genetic Information Nondiscrimination Act of US</i>	14
<i>Impact of the US health care reform bill on genetic testing issues</i>	14
Patents for molecular diagnostics	14
PCR patents	14
Patenting DNA sequences	14
US policy on gene patenting relevant to molecular diagnostics.....	15
The impact of disease gene patents on molecular diagnostics	16
Licensing problems associated with genetic testing	16
BRCA1 and BRCA2 gene patents	16
Role of the WHO in genetic testing standards	17
NIH's Genetic Testing Registry	18
Regulatory issues in the US	18
Assay Migration Studies for In Vitro Diagnostic Devices	18
Assessment of diagnostic accuracy	18
<i>Sensitivity and specificity</i>	19
<i>Documentation of diagnostic accuracy</i>	19
Discovery of incidental findings on genetic screening	20
Evaluation of companion diagnostics/therapeutic for cancer	21
FDA regulation of multivariate index assays	21
FDA guidance for IVDs to detect pathogens	22
FDA guidelines for devices to detect and differentiate HPV	23
FDA's Microarray Quality Control.....	23
FDA and point-of-care diagnosis	24
Genetic testing of rare disorders	24
Guidelines for developing omics-based tests.....	25
<i>Shared responsibility on oversight of omics-based tests</i>	25
Guidelines for use of sequencing for diagnosis	26
Quality control of molecular diagnostic laboratory procedures	27
Quality assurance of rna expression profiling	27
Quality control of point-of-care tests	28
Regulation of IVD by the FDA	28
Regulation of in vitro companion diagnostics by the FDA.....	29
Regulation of in vivo diagnostics by the FDA.....	30
Regulation of laboratory developed tests.....	31
<i>Home-brew tests</i>	31
<i>Laboratory-developed tests used by Medicare recipients</i>	31
<i>Oversight of LDTs by the FDA</i>	32
Regulatory aspects of FISH	32
Regulation of genetic testing	32
<i>Role of the FDA in genetic testing</i>	32
Regulation of direct-to-consumer genetic testing	33
<i>Need for regulatory oversight of DTC</i>	33
Regulatory issues concerning blood and plasma products.....	35
United States Diagnostics Standards	35
Regulation of in vitro diagnostics in the EU	36
EU regulations for testing of blood products	36
Regulation of genetic testing in EU	36
Evaluation of diagnostic laboratory tests in the UK	38
Pre-implantation genetic diagnosis in the UK	38

13. Markets for Molecular Diagnostics	40
Introduction	40
Methods for study of molecular diagnostic markets.....	40
The overall market for diagnostic technologies	41
Molecular diagnostic markets according to technologies	41
Marketing strategies according to technologies	42
Nucleic acid isolation market	42
Market for PCR-based tests	42
<i>Markets for PCR instrumentation.....</i>	42
<i>Markets for real-time PCR and qRT-PCR.....</i>	43
<i>PCR market players.....</i>	43
DNA sequencing market.....	44
Cytogenetic market.....	44
<i>Market for FISH technologies.....</i>	44
Biochip/microarray market.....	45
Biosensor market.....	45
Nanobiotechnology for molecular diagnostics.....	45
Markets for gene expression technologies	46
Reagents and other disposable laboratory materials	46
Market for immunochemistry diagnostic.....	46
Markets for tissue diagnostics.....	46
Molecular diagnostic markets according to therapeutic areas	46
Genetic disorders.....	47
Prenatal testing	48
Cancer.....	48
<i>Potential markets for cancer diagnosis according to type of cancer.....</i>	49
Infectious diseases.....	50
<i>Sexually transmitted diseases.....</i>	52
<i>Hospital-acquired infections.....</i>	52
<i>Testing for HIV drug resistance.....</i>	53
<i>Potential markets for avian influenza diagnostics</i>	53
Cardiovascular diseases	54
Neurological disorders	54
Food testing	54
Screening of blood for transfusion.....	55
Tissue typing for transplantation.....	55
Molecular diagnostic markets relevant to pharmaceutical industry	55
Molecular diagnosis and personalized medicine markets.....	55
Growth of markets relevant to personalized medicine	55
Marketing opportunities according to geographic areas	56
Unmet needs in molecular diagnostics.....	57
Major market trends	57
Markets according to home-brew and FDA-approved tests	57
Decentralization of molecular diagnostics	58
Point-of-care testing.....	58
Development of personalized medicine	59
<i>Cost of sequencing the human genome.....</i>	59
<i>Cost of genotyping.....</i>	60
<i>Marketing companion diagnostics for personalized medicine</i>	60
Development of low-cost tests	61
Simplification of test procedures	61
Increasing role of proteomics in clinical diagnostics	61
Forensic and legal applications	62
Veterinary molecular diagnostics.....	62
Marketing strategies.....	62
Role of alliances in commercialization of molecular diagnostics	63
<i>Acquisitions vs collaborations</i>	63
<i>Analysis of collaborations in molecular diagnostics</i>	66
<i>Licensing of the technologies.....</i>	67
Strategies related to laboratory facilities and technologies	67
Strategies relevant to the healthcare system.....	68
<i>Cost-Benefit studies</i>	68
<i>Genetic susceptibility testing</i>	68
<i>Preventive medicine strategies</i>	69
<i>Targeting treatable and common diseases.....</i>	69
Information/education	69
<i>Physician education.....</i>	69
<i>Patient education</i>	70
<i>European diagnostic information platform</i>	70
Regulatory strategies	71
Merger of in vitro and in vivo diagnostics	71

Integration of diagnostics with therapeutics	71
Diagnostic applications in clinical trials	71
Prospects for development of new technologies.....	72
Drivers for the development of molecular diagnostics	72
Factors slowing the development of molecular diagnostics	72
Government support of research relevant to molecular diagnostics	73
<i>Cost of sequencing the human genome.....</i>	<i>73</i>
European projects for improving molecular diagnostics	75
<i>European Consortium for developing new DNA analysis tools.....</i>	<i>75</i>
<i>EU project for improvement of IVD tools procedures</i>	<i>76</i>
<i>Genetic knowledge parks in the UK</i>	<i>76</i>
Molecular diagnostic opportunities in defense against bioterrorism	76
Molecular diagnostics for food safety	77
POC diagnostics for the developing countries.....	77
14. Companies involved in molecular diagnostics	78
Introduction	78
Major players in molecular diagnostics.....	78
Profiles of selected companies.....	79
Collaborations.....	467

Tables

Table 13-1: Share of in vitro diagnostics in the global diagnostic market 2011-2021.....	41
Table 13-2: Molecular diagnostics markets according to technologies from 2011-2021	41
Table 13-3: PCR market 2011-2021	42
Table 13-4: Molecular diagnostics markets according to applications 2011-2021.....	47
Table 13-5: Markets in 2011 for tests to screen healthy persons for genetic disorders.....	48
Table 13-6: Markets in 2011 for molecular diagnostic screening tests for cancer.....	49
Table 13-7: Molecular diagnostic markets for selected cancers 2011-2021	49
Table 13-8: Markets value in 2011 for molecular diagnostic screening for infections.....	51
Table 13-9: Future markets for molecular diagnosis of infections 2012-2016.....	51
Table 13-10: Future markets for HAI diagnostics 2012-2016.....	52
Table 13-11: Growth of markets relevant to personalized medicine 2011-2021	56
Table 13-12: Molecular diagnostic markets according to geographical areas 2011-2021	56
Table 13-13: Molecular diagnostic markets according to home-brew and approved tests	58
Table 13-14: Marketing strategies for molecular diagnostics	62
Table 13-15: Acquisitions of molecular diagnostic companies	63
Table 13-16: Advantages of the integration of diagnostics with therapeutics	71
Table 14-1: Top ten players in molecular diagnostics	78
Table 14-2: Collaborations of companies in molecular diagnostics	467

Figures

Figure 13-1: Unmet needs in applications of molecular diagnostics	57
Figure 13-2: Proportion of various areas in molecular diagnostic collaborations	67